Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID

Health newsHealth & Medical News › Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID

Story Photo: Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID
Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID

"Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin"

Poster presenter: Derrick Crook, M.D.

Saturday, April 10, 2010 3:30pm–4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2401

"Three simple ESCMID severity criteria predict poor cure rate and slower resolution of diarrhea in Clostridium difficile infection"

Poster presenter: Mark A. Miller, M.D.

Saturday, April 10, 2010 3:30pm-4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2394

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. Optimer has reported positive top-line results from two Phase 3 trials of fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.

Source: PRNewsWire Health News Release

Link this story to your website:

Copy the above code and paste it into your webpage, blog or forum

Comments On Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID

This news has no comments.

Be the first one to comment on this news

Add Comment

Your Comment
Your Name
Your Email

Your Email will not be shown with your comment

Secret Number
347

Please type the numbers shown above into the Secret Number box.

Most Popular Tags

eccmid fidaxomicin

,